Stonepine Capital Management, LLC Buys Affimed NV, Amarin Corp PLC, Adamas Pharmaceuticals Inc, Sells BioDelivery Sciences International Inc, Enanta Pharmaceuticals Inc, Ligand Pharmaceuticals Inc

• New Purchases: EOLS, CBIO, SBBP, SCYX, PF42, TORC,
• Added Positions: AFMD, AMRN, ADMS, APEN, NEOS, APVO, CHMA, OPNT, CPIX, NVLNF, CTIC,
• Reduced Positions: ISEE, OXFD, HTGM, XOMA, ACER,
• Sold Out: BDSI, ENTA, LGND, ALIM, CORV, IDXG, KALV, RTRX, DRRX, F2KA,

For the details of Stonepine Capital Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/stonepine+capital+management%2C+llc/current-portfolio/portfolio

1. Amarin Corp PLC (AMRN) - 1,551,300 shares, 23.65% of the total portfolio. Shares added by 25.15%
2. IVERIC bio Inc (ISEE) - 3,000,000 shares, 18.31% of the total portfolio. Shares reduced by 21.59%
3. Affimed NV (AFMD) - 4,010,155 shares, 7.81% of the total portfolio. Shares added by 5008.48%
4. Oxford Immunotec Global PLC (OXFD) - 630,862 shares, 7.45% of the total portfolio. Shares reduced by 7.47%
5. Adamas Pharmaceuticals Inc (ADMS) - 2,241,239 shares, 6.04% of the total portfolio. Shares added by 198.43%

Stonepine Capital Management, LLC initiated holding in Evolus Inc. The purchase prices were between $11.58 and $17.37, with an estimated average price of $14.05. The stock is now traded at around $9.39. The impact to a portfolio due to this purchase was 3.42%. The holding were 394,890 shares as of .

Stonepine Capital Management, LLC initiated holding in Catalyst Biosciences Inc. The purchase prices were between $4.77 and $7.91, with an estimated average price of $5.63. The stock is now traded at around $6.60. The impact to a portfolio due to this purchase was 1.49%. The holding were 307,287 shares as of .

Stonepine Capital Management, LLC initiated holding in Strongbridge Biopharma PLC. The purchase prices were between $1.47 and $2.42, with an estimated average price of $1.91. The stock is now traded at around $3.08. The impact to a portfolio due to this purchase was 0.64%. The holding were 431,853 shares as of .

Stonepine Capital Management, LLC initiated holding in SCYNEXIS Inc. The purchase prices were between $0.72 and $1.35, with an estimated average price of $1.03. The stock is now traded at around $1.11. The impact to a portfolio due to this purchase was 0.39%. The holding were 609,384 shares as of .

Stonepine Capital Management, LLC initiated holding in Interpace Biosciences Inc. The purchase prices were between $3.42 and $7.45, with an estimated average price of $5.71. The stock is now traded at around $9.80. The impact to a portfolio due to this purchase was 0.34%. The holding were 94,385 shares as of .

Stonepine Capital Management, LLC initiated holding in resTORbio Inc. The purchase prices were between $1.07 and $9.27, with an estimated average price of $4.36. The stock is now traded at around $1.52. The impact to a portfolio due to this purchase was 0.09%. The holding were 81,772 shares as of .

Stonepine Capital Management, LLC added to a holding in Affimed NV by 5008.48%. The purchase prices were between $2.25 and $3.07, with an estimated average price of $2.68. The stock is now traded at around $2.49. The impact to a portfolio due to this purchase was 7.66%. The holding were 4,010,155 shares as of .

Stonepine Capital Management, LLC added to a holding in Amarin Corp PLC by 25.15%. The purchase prices were between $13.94 and $24.12, with an estimated average price of $19.16. The stock is now traded at around $17.38. The impact to a portfolio due to this purchase was 4.75%. The holding were 1,551,300 shares as of .

Stonepine Capital Management, LLC added to a holding in Adamas Pharmaceuticals Inc by 198.43%. The purchase prices were between $3.44 and $7.3, with an estimated average price of $4.79. The stock is now traded at around $5.33. The impact to a portfolio due to this purchase was 4.02%. The holding were 2,241,239 shares as of .

Stonepine Capital Management, LLC added to a holding in Aptevo Therapeutics Inc by 22.43%. The purchase prices were between $0.53 and $0.7, with an estimated average price of $0.61. The stock is now traded at around $0.48. The impact to a portfolio due to this purchase was 0.36%. The holding were 4,179,131 shares as of .

Stonepine Capital Management, LLC added to a holding in Chiasma Inc by 67.35%. The purchase prices were between $4.57 and $5.55, with an estimated average price of $5.22. The stock is now traded at around $4.40. The impact to a portfolio due to this purchase was 0.26%. The holding were 183,660 shares as of .

Stonepine Capital Management, LLC sold out a holding in BioDelivery Sciences International Inc. The sale prices were between $4.51 and $7.06, with an estimated average price of $5.92.

Stonepine Capital Management, LLC sold out a holding in Enanta Pharmaceuticals Inc. The sale prices were between $57.95 and $66.61, with an estimated average price of $62.03.

Stonepine Capital Management, LLC sold out a holding in Ligand Pharmaceuticals Inc. The sale prices were between $96.94 and $113.59, with an estimated average price of $107.38.

Stonepine Capital Management, LLC sold out a holding in Alimera Sciences Inc. The sale prices were between $3.3 and $9.44, with an estimated average price of $5.96.

Stonepine Capital Management, LLC sold out a holding in Correvio Pharma Corp. The sale prices were between $0.35 and $2.45, with an estimated average price of $1.64.

Stonepine Capital Management, LLC sold out a holding in Interpace Biosciences Inc. The sale prices were between $3.98 and $8.3, with an estimated average price of $6.39.

Stonepine Capital Management, LLC reduced to a holding in IVERIC bio Inc by 21.59%. The sale prices were between $0.93 and $8.58, with an estimated average price of $3.67. The stock is now traded at around $5.76. The impact to a portfolio due to this sale was -0.9%. Stonepine Capital Management, LLC still held 3,000,000 shares as of .

Stonepine Capital Management, LLC reduced to a holding in Acer Therapeutics Inc by 82.48%. The sale prices were between $2.85 and $4.2, with an estimated average price of $3.42. The stock is now traded at around $4.97. The impact to a portfolio due to this sale was -0.29%. Stonepine Capital Management, LLC still held 20,000 shares as of .